Abstract | BACKGROUND: METHODS: We examine available literature and ongoing clinical trials with ipilimumab and tremelimumab and review our own experience with patients treated with CTLA-4 blockade, with an emphasis on issues of direct relevance to surgical oncologists. RESULTS: CONCLUSIONS: As more patients are enrolled onto clinical trials involving ipilimumab and tremelimumab, an increasing number of surgeons may be involved in the care of these patients who develop treatment-related complications. In this report, we review the rationale for CTLA-4 blockade and review selected clinical studies published so far with ipilimumab and tremelimumab. We offer guidelines on the management of patients who develop enterocolitis.
|
Authors | Giao Q Phan, Jeffrey S Weber, Vernon K Sondak |
Journal | Annals of surgical oncology
(Ann Surg Oncol)
Vol. 15
Issue 11
Pg. 3014-21
(Nov 2008)
ISSN: 1534-4681 [Electronic] United States |
PMID | 18716842
(Publication Type: Journal Article, Review)
|
Chemical References |
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Antigens, CD
- CTLA-4 Antigen
- CTLA4 protein, human
- Ipilimumab
- tremelimumab
|
Topics |
- Antibodies, Monoclonal
(adverse effects, therapeutic use)
- Antibodies, Monoclonal, Humanized
- Antigens, CD
(immunology)
- CTLA-4 Antigen
- Clinical Trials as Topic
- Enterocolitis
(chemically induced, drug therapy)
- Guidelines as Topic
- Humans
- Immunotherapy
- Ipilimumab
- Melanoma
(drug therapy, pathology)
- Neoplasm Metastasis
|